文献速递心脑血管急症重症综合管理与镇静镇痛

大梗死核心急性缺血性卒中血管内治疗试验

Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct.
PubMed 文献 · N Engl J Med · 2023-02-10
一句话结论中国多中心RCT显示,前循环大血管闭塞且大梗死核心患者24小时内血管内治疗可改善90天mRS分布,但颅内出血更多。

该多中心、前瞻性、开放标签、随机试验在中国纳入前循环大血管闭塞且ASPECTS 3–5分或梗死核心体积70–100 ml的急性缺血性卒中患者,随机接受血管内治疗联合内科管理或单纯内科管理,主要终点为90天mRS评分分布偏移。共456例入组(血管内治疗组231例,内科管理组225例),约28%患者接受静脉溶栓。第二次中期分析后因血管内治疗有效而提前终止;90天mRS分布向更好结局偏移(广义优势比1.37;95%CI 1.11–1.69;P=0.004)。症状性颅内出血血管内治疗组14/230例(6.1%)vs 内科管理组6/225例(2.7%),任何颅内出血分别为113例(49.1%)vs 39例(17.3%)。

要点

  • 中国多中心RCT:前循环大血管闭塞、ASPECTS 3–5分或梗死核心70–100 ml患者,24小时内血管内治疗使90天mRS分布向更好结局偏移(广义优势比1.37;95%CI 1.11–1.69;P=0.004)。
  • 症状性颅内出血血管内治疗组14/230例(6.1%)vs 内科管理组6/225例(2.7%);任何颅内出血113例(49.1%)vs 39例(17.3%)。
  • 两组约28%患者接受静脉溶栓;试验在第二次中期分析后因血管内治疗有效而提前终止。

适用人群与场景

  • 中国多中心、前瞻性、开放标签、随机试验纳入的前循环大血管闭塞急性缺血性卒中患者,ASPECTS 3–5分(范围0–10分,分值越低梗死越大)或梗死核心体积70–100 ml,距最后已知良好时间24小时内随机。
  • 随机1:1接受血管内治疗联合内科管理或单纯内科管理;约28%的患者两组均接受静脉溶栓。

诊断标准与关键阈值

  • ASPECTS 3–5分(范围0–10分,分值越低提示梗死范围越大)或梗死核心体积70–100 ml。
  • 前循环大血管闭塞。
  • 距最后已知良好时间24小时内随机。

研究设计与关键结果

  • 多中心、前瞻性、开放标签、随机试验,共456例患者入组,血管内治疗组231例,内科管理组225例;约28%的患者两组均接受静脉溶栓。
  • 主要终点:90天mRS评分分布向更好结局偏移,支持血管内治疗优于单纯内科管理(广义优势比1.37;95%CI 1.11–1.69;P=0.004)。
  • 症状性颅内出血:血管内治疗组14/230例(6.1%)vs 内科管理组6/225例(2.7%);任何颅内出血:血管内治疗组113例(49.1%)vs 内科管理组39例(17.3%)。
  • 次要结局(mRS 0–2分和0–3分)结果总体支持主要分析。
  • 试验在第二次中期分析后因血管内治疗有效而提前终止。

证据类型、等级与局限

  • 证据类型:多中心、前瞻性、开放标签、随机试验。
  • 试验因血管内治疗有效在第二次中期分析后提前终止。

对床旁实践的改变

  • 作者结论:在中国开展的试验中,大梗死核心患者24小时内接受血管内治疗较单纯内科管理结局更好,但颅内出血更多。

指南或共识出处

  • ANGEL-ASPECT试验(ClinicalTrials.gov NCT04551664),由Covidien Healthcare International Trading(Shanghai)等资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The role of endovascular therapy for acute stroke with a large infarction has not been extensively studied in differing populations.

METHODS: We conducted a multicenter, prospective, open-label, randomized trial in China involving patients with acute large-vessel occlusion in the anterior circulation and an Alberta Stroke Program Early Computed Tomography Score of 3 to 5 (range, 0 to 10, with lower values indicating larger infarction) or an infarct-core volume of 70 to 100 ml. Patients were randomly assigned in a 1:1 ratio within 24 hours from the time they were last known to be well to undergo endovascular therapy and receive medical management or to receive medical management alone. The primary outcome was the score on the modified Rankin scale at 90 days (scores range from 0 to 6, with higher scores indicating greater disability), and the primary objective was to determine whether a shift in the distribution of the scores on the modified Rankin scale at 90 days had occurred between the two groups. Secondary outcomes included scores of 0 to 2 and 0 to 3 on the modified Rankin scale. The primary safety outcome was symptomatic intracranial hemorrhage within 48 hours after randomization.

RESULTS: A total of 456 patients were enrolled; 231 were assigned to the endovascular-therapy group and 225 to the medical-management group. Approximately 28% of the patients in both groups received intravenous thrombolysis. The trial was stopped early owing to the efficacy of endovascular therapy after the second interim analysis. At 90 days, a shift in the distribution of scores on the modified Rankin scale toward better outcomes was observed in favor of endovascular therapy over medical management alone (generalized odds ratio, 1.37; 95% confidence interval, 1.11 to 1.69; P = 0.004). Symptomatic intracranial hemorrhage occurred in 14 of 230 patients (6.1%) in the endovascular-therapy group and in 6 of 225 patients (2.7%) in the medical-management group; any intracranial hemorrhage occurred in 113 (49.1%) and 39 (17.3%), respectively. Results for the secondary outcomes generally supported those of the primary analysis.

CONCLUSIONS: In a trial conducted in China, patients with large cerebral infarctions had better outcomes with endovascular therapy administered within 24 hours than with medical management alone but had more intracranial hemorrhages. (Funded by Covidien Healthcare International Trading [Shanghai] and others; ANGEL-ASPECT ClinicalTrials.gov number, NCT04551664.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Huo X, Ma G, Tong X, et al. Trial of Endovascular Therapy for Acute Ischemic Stroke with Large Infarct. N Engl J Med. 2023. PMID: 36762852. doi:10.1056/NEJMoa2213379

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。